Salazar VJJ, León QGI

Language: Spanish
References: 27
Page: 289-293
PDF size: 126.76 Kb.

ABSTRACT

Background: drug-induced skin reactions are an infrequent but important cause of morbidity and mortality.
Objectives: The goal of this study is to analyze the characteristics of patients who developed drug-induced skin reactions in response to anticonvulsant drugs in a specialty hospital.
Methods: the data was collected retrospectively in the time between January 2004 and December 2014. The following data was collected: age, sex, comorbidities, triggering drug, latency period, type of reaction, systemic complications, hospital stay, and treatment.
Results: the data was collected from 12 patients. The mean age was 29.5 years. All patients had comorbidities, the most common causative agent was sodium diphenylhydantoinate. The most common type of reaction was Stevens Johnson Syndrome with six cases, followed by morbilliform exanthem with four cases and overlap syndrome with two cases.
Conclusions: sodium diphenylhydantoinate was the most common triggering drug, the most commonly observed reaction was ssj, and the treatment of drug-induced skin reactions in early stages has a low complication index.

REFERENCES

1. Hihara, K., Kano, Y., Sato, Y., Horie, C., Okazaki, A., Ishida, T., Aoyama, Y. y Shiohara, T., “Metilprednisolone pulse therapy for Stevens Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers”, J Am AcadDermatol, 2013, 69: 496-497.

2. Bloch, K.M., Sills, G.J., Pirmohead, M. y Alfirevic, A., “Pharmacogenetics of antiepileptic drug-induced hypersensitivity”, Pharmacogenomics, 2014, 15: 857-868.

3. Su, P. y Aw, C.W.D., “Severe cutaneous adverse reactions in a local hospital setting: a 5 years retrospective study”, Int J Dermatol, 2014, 53: 1339-1345.

4. Saka, B., Barro-Traoré, F., Atadokpédé, F.A., Kobangue, L., Niamba, P.A., Adégbidi, H., Yedemon, H.G., Traoré, A. y Pitché, V.P., “Stevens Johnson syndrome and toxic epidemal necrolysis in sub-Saharan Africa: a multicentric study four countries”, Int J Dermatol, 2013, 52: 575-579.

5. Firoz, B.F., Henning, J.S., Zarzabal, L.A. y Pollock, B.H., “Toxic epidermal necrolysis: five years of treatment experience from a burn unit”, J Am Acad Dermatol, 2012, 67: 630-635.

6. Lee, H.Y., Lim, Y.L., Thirumoorthy, T. Pang, S.M., “The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre”, Br J Dermatol, 2013, 169: 1304-1309.

7. Yang, Y., Xu, J., Feng, L. y Zhu, X., “Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China”, Int J Dermatol, 2009, 48: 1122-1128.

8. Gómez-Criado, M.S., Ayani, I., León-Colombo, T., Ramos, M.L. y Reneses, M.J., “Síndrome de Stevens-Johnson, necrólisis epidérmica tóxica y fenitoína. Factores asociados a un aumento de riesgo”, Rev Neurol, 2004, 38: 1056-1060.

9. Schwartz, R.A., McDonough, P.H. y Lee, B.W., “Toxic epidermal necrolysis. Introduction, history, classification, clinical features, systemic manifestations, etiology and immunopathogeneses”, J Am Acad Dermatol, 2013, 69: 173-186.

10. Reynoso-von Drateln, C., Villagrán, P.M., Rodríguez-Martínez, N., Acosta-Ramírez, C., Alcántar-Luna, E. y Torres-Garibay, C., “Abordaje terapéutico del síndrome de necrólisis epidérmica tóxica (síndrome de Brocq-Lyell)”, Derm Rev Mex, 2009, 53: 288-294.

11. Urosevic-Maiwald, M., Harr, T., French, L.E., y Dummer, R., “Stevens- Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving rituximab and radiotherapy for head and neck cancer”, Int J Dermatol, 2012, 51: 864-867.

12. Paradisi, A., Abeni, D., Bergamo, F., Ricci, F., Didona, D. y Didona, B., “Etarnecept therapy for toxic epidermal necrolysis”, J Am Acad Dermatol, 2014, 71: 278-283.

13. Das, K.K., Khondokar, S., Rahman, A. y Chakraborty, A., “Unidentified drugs in traditional medications causing toxic epidermal necrolysis: a developing country experience”, Int J Dermatol, 2014, 53: 510-515.

14. Ding, W.Y., Lee, C.K. y Choon, S.E., “Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia”, Int J Dermatol, 2010, 49: 834-841.

15. Vern-Gross, T.Z. y Kowal-Vern, A., “Erythema multiform, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy. A literature review”, Am J Clin Oncology, 2014, 37: 506-513.

16. Genin, E., Chen, D.P., Hung, S.I., Sekula, P., Schumacher, M., Chang, P.Y., Tsai, S.H., Wu, T.L., Bellón, T., Tamouza, R., Fortier, C., Toubert, A., Charron, D., Hovnanian, A., Wolkenstein, P., Chung, W.H., Mockenahupt, M. y Roujeau, J.C., “hla-a*31:01 and different types of carbamazepine- induced severe cutaneous reactions: an international study and meta-analysis”, The Pharmacogenomics J, 2014, 14: 281-288.

17. Van-Nguyen, D., Chu, H.C., Phan, M.H., Timothy, C., Bumgart, K. y Van Nunen, S., “hla-b*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese”, Asia Pac Allergy, 2015, 5: 68-77.

18. Claudle, K.E., Rettie, A.E., Whirl-Carrilo, M., Smith, L.H., Mintzer, S., Lee, M.T.M., Klein, T.E. y Callaghan, J.T., “Clinical pharmacogenetics implementation consortium guidelines for cyp2c9 and hla-b genotypes and phenytoin dosing”, Nature, 2014, 69: 542-548.

19. Zeng, T., Long, S., Min, F., Liao, P. y Shi, W., “Association of hla-b*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjets: a meta-analysis”, Int J Dermatol, 2015, 54: 488-393.

20. Schwartz, R.A., McDonough, P.H. y Lee, B.W., “Toxic epidermal necrolysis. Prognosis, sequelae, diagnosis, differential diagnosis, prevention and treatment”, J Am Acad Dermatol, 2013, 69: 187-202.

21. Aihara, M., Kano, Y., Fujita, H., Kambara, T., Matsukura, S., Katayama, I., Azukizawa, H., Miyachi, Y., Endo, Y., Asada, H., Miyagawa, F., Morita, E., Kaneko, S., Abe, R., Ochiai, T., Sueki, H., Watanabe, H., Nagao, K., Aoyama, Y., Sayama, K., Hashimoto, K. y Shiohara, T., “sjs/ten study group. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis”, J Dermatol, 2015, 42: 1-10.

22. Ririe, M.R., Blaylock, R.C., Morris, S.E. y Jung Jae, Y., “Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal complicated by hemolysis leading to pigment nephropathy a hemodialysis”, J Am Acad Dermatol, 2013, 69: 221-226.

23. Sadighha A. Etarnecept in the treatment of a patient with acute generalized exanthematouspustulosis/toxic epidermal necrolysis: definition of a new model based on translational research. Int J Dermatol 2009; 48:913-14.

24. Kirchof, M.G., Miliszewski, M.A., Sikora, S., Papp, A. y Dutz, J.P., “Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine”, J Am Acad Dermatol, 2014, 71: 941-947.

25. Bocquet, H., Farmer, M., Bressieux, J.M., Barzegar, C., Jullien, M., Soto, B. y Roujeau, J.C., “Revuz. Toxic epidermal necrolysis and Stevens-Johnson syndrome with lamotrigine”, Ann Dermatol Venereol, 1999, 126: 46-49.

26. Ertam, I., Sezgin, A.O. y Unal, I., “A case with Stevens Johnson Syndrome triggered by combination of clobazam, lamotrigine and valproic acid treatment”, Int J Dermatol, 2009, 48: 98-99.

27. Wang, X.Q., Li, B., Wang, H.F., Zhang, X., Yu, S.Y., Huang, X.S., Zhang, J.T., Tian, C.L. y Lang, S.Y., “Lamotrigin-induced severe cutaneous adverse reaction: update data from 1999-2014”, J Clin Neurosci, 2015, 22: 1005-1011.